Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 130-134

  Aschmann, Yvonne Zysset ^a   Kummer, Oliver ^a   Linka, André ^a   Wenk, Markus ^a   Azzola, Andrea ^a   Bodmer, Michael ^a   Krähenbühl, Stephan ^a   Haschke, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Human immunodeficiency virus infection; Protease inhibitors; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

INDINAVIR; LOPINAVIR; RITONAVIR; SILDENAFIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; ELECTROCARDIOGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ADULT; AREA UNDER CURVE; DRUG INTERACTIONS; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; PURINES; REFERENCE VALUES; SULFONES; VASODILATOR AGENTS;

EID: 38549181201     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318165ba71     Document Type: Article

References (25)

1. Mehta NJ, Khan IA, Mehta RN, et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest. 2000;118:1133-1141.
2. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S.
3. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281:421-426.
4. Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol. 1999;46:15-21.
5. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
6. D'Amours MR, Granovsky AE, Artemyev NO, et al. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme. Mol Pharmacol. 1999;55:508-514.
7. Cohen AH, Hanson K, Morris K, et al. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996;97:172-179.
8. Beavo JA. cGMP inhibition of heart phosphodiesterase: is it clinically relevant? J Clin Invest. 1995;95:445.
9. Das S, Kumar KN. Nitric oxide: its identity and role in blood pressure control. Life Sci. 1995;57:1547-1556.
10. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
11. Warrington JS, Shader RI, von Moltke LL, et al. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000;28:392-397.
12. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44:190-194.
13. Muirhead GJ, Faulkner S, Harness JA, et al. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol. 2002;53(Suppl 1):37S-43S.
14. Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000;50:99-107.
15. Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999;13:F101-F107.
16. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53(Suppl 1):5S-12S.
17. Eidem BW, Tei C, O'Leary PW, et al. Nongeometric quantitative assessment of right and left ventricular function: myocardial performance index in normal children and patients with Ebstein anomaly. J Am Soc Echocardiogr. 1998;11:849-856.
18. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function. A study in normals and dilated cardiomyopathy. J Cardiol. 1995;26:357-366.
19. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996;9:838-847.
20. Lee M, Min DI. Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. Ther Drug Monit. 2001;23:21-26.
21. European Medicines Agency. Revatio® scientific discussion (report EMEA/H/C/638). European Public Assessment Report. 2005.
22. Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312:583-591.
23. Dussault I, Lin M, Hollister K, et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Bio Chem. 2001;276:33309-33312.
24. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002;1:259-266.
25. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584-590.